Related Experiment Video

Updated: Mar 8, 2026

An In vitro Model to Study Immune Responses of Human Peripheral Blood Mononuclear Cells to Human Respiratory Syncytial Virus Infection
09:01

An In vitro Model to Study Immune Responses of Human Peripheral Blood Mononuclear Cells to Human Respiratory Syncytial Virus Infection

Published on: December 10, 2013

8.4K

Respiratory Syncytial Virus Infection: An Illness for All Ages

Edward E Walsh1

  • 1Infectious Diseases Division, Department of Medicine, Rochester General Hospital, University of Rochester School of Medicine, 1425 Portland Avenue, Rochester, NY 14621, USA.

Clinics in Chest Medicine
|February 5, 2017
PubMed

Insights

Respiratory syncytial virus (RSV) causes severe respiratory illness in infants and vulnerable adults. New vaccines and antivirals show promise for preventing and treating RSV infections.

Area of Science:

  • * Virology and Immunology
  • * Pediatric and Geriatric Respiratory Medicine

Background:

  • * Respiratory syncytial virus (RSV) is a primary cause of severe lower respiratory tract infections in infants.
  • * RSV is increasingly recognized as a significant pathogen in elderly adults, individuals with cardiopulmonary conditions, and the immunocompromised.
  • * A potential link exists between RSV infection and the development of asthma.

Purpose of the Study:

  • * To review the current understanding of RSV as a pathogen.
  • * To highlight the limitations of existing prophylactic measures.
  • * To discuss emerging vaccine and antiviral strategies for RSV.

Main Methods:

  • * Literature review of RSV epidemiology, pathogenesis, and clinical impact.
  • * Analysis of current prophylactic and therapeutic options.
  • * Examination of recent advancements in vaccine and antiviral development.

Main Results:

  • * Monoclonal antibody prophylaxis is currently the sole specific therapy for high-risk infants.
  • * Significant progress has been made in developing novel RSV vaccines and antiviral drugs.
  • * These new agents hold promise for both prevention and treatment across various risk groups.

Conclusions:

  • * RSV remains a critical public health concern, particularly for infants and vulnerable adult populations.
  • * Breakthroughs in vaccine and antiviral research offer hope for improved control of RSV.
  • * Future strategies will likely involve a combination of prophylaxis and therapeutics to combat RSV infection.

Keywords:
AdultsAntiviralsAsthmaBronchiolitisChronic obstructive pulmonary diseaseRespiratory syncytial virusVaccines

More Related Videos

Generation, Amplification, and Titration of Recombinant Respiratory Syncytial Viruses11:48

Generation, Amplification, and Titration of Recombinant Respiratory Syncytial Viruses

Published on: April 4, 2019

17.4K
An Improved and High Throughput Respiratory Syncytial Virus RSV Micro-neutralization Assay09:14

An Improved and High Throughput Respiratory Syncytial Virus RSV Micro-neutralization Assay

Published on: January 26, 2019

11.6K

Related Concept Videos

Pulmonary Cycle: Exhalation01:17

Pulmonary Cycle: Exhalation

In terms of human respiration, the act of expelling air, known as exhalation (or expiration), operates on the principle of pressure gradients. During expiration, the pressure within the lungs exceeds that of the surrounding atmosphere. Under normal conditions, quiet breathing involves passive exhalation and is free of muscular contractions. This is because the exhalation process is driven by the natural elastic recoil of the lungs and chest wall, both of which have an inherent tendency to...
4.4K
Common Respiratory Disorders01:31

Common Respiratory Disorders

Respiratory disorders, a prevalent health concern globally, are generally divided into two primary categories: upper and lower respiratory tract disorders. The categorization is based on the area of the respiratory system they affect.
Upper respiratory disorders impact the airways above the vocal cords, encompassing areas like the nose, sinuses, and throat. Various conditions fall under this category, including the common cold and allergic rhinitis. These disorders can stem from several causes,...
1.7K
Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...
6.5K
Acute Respiratory Failure-II01:21

Acute Respiratory Failure-II

Type I Respiratory Failure, or hypoxemic respiratory failure, occurs when the partial pressure of oxygen (PaO2) in arterial blood falls below 60 mmHg while breathing room air without a corresponding increase in arterial carbon dioxide levels (PaCO2). This condition highlights a significant impairment in the lungs' capacity to oxygenate the blood.
The underlying physiological abnormalities that contribute to hypoxemic respiratory failure include:
1.3K
Acute Respiratory Failure-I01:21

Acute Respiratory Failure-I

Acute respiratory failure is a condition characterized by the inability of the lungs to perform their primary function: gas exchange. This failure leads to insufficient oxygen levels (hypoxemia) in the blood, elevated carbon dioxide levels (hypercapnia), or both, causing critical impairment in organ function.
Definition: It is defined by specific criteria based on blood gas measurements. Hypoxemia happens when the partial pressure of oxygen (PaO2) falls below 60 mmHg. At the same time,...
1.3K
Acute Respiratory Failure-V01:29

Acute Respiratory Failure-V

The treatment for acute respiratory failure varies based on factors like the underlying cause, overall health, and severity. A collaborative healthcare team is essential for early detection, often through arterial blood gas analysis. Identifying the cause is the primary goal, with treatment strategies adjusted for ventilation/perfusion (V/Q) mismatch, shunting, or diffusion impairment.
Ensure that patients are monitored continuously for their response to therapy, including changes in...
572